Showing 7261-7270 of 7634 results for "".
- Onset Dermatologics Unveils Anti-Itch Gel for Eczemahttps://practicaldermatology.com/news/20130515-onset_unveils_anti-itch_gel_for_eczema/2459544/A new product for itching associated with eczema is now available from Onset Dermatologics. Aurstat® Anti-Itch Hydrogel is engineered to soothe itching, burning, and pain of atopic dermatitis and various dermatoses, according to the company. The patented hydrogel formulation is alcohol free, fragran
- JUVÉDERM VOLUMA™ XC Receives Unanimous Recommendation from FDA Panelhttps://practicaldermatology.com/news/20130514-juvderm_voluma_xc_receives_unanimous_recommendation_from_fda/2459545/The US Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee voted unanimously that the benefits of JUVÉDERM VOLUMA™ XC, an injectable hyaluronic acid dermal filler for cheek augme
- Outrun the Sun Partners with Girls on the Run International for Sun Safetyhttps://practicaldermatology.com/news/20130513-outrun_the_sun_partners_with_girls_on_the_run_international_for_sun_safety/2459547/Outrun the Sun, Inc. and Girls on the Run International recently partnered up to provide sun safety education for Girls on the Run participants across America and Canada. This year, t
- Thermage Total Tip Available to Dermatologists Nationwidehttps://practicaldermatology.com/news/20130510-thermage_total_tip_available_to_dermatologists_nationwide/2459548/Solta Medical, Inc. launched the Thermage Total Tip 3.0 for face, neck, and body treatments. Targeted, uniform, bulk heating allows dermatologists to treat patients effectively while maintaining patient comfort, according to the company. Thermage
- Free Skin Health Screenings This Weekendhttps://practicaldermatology.com/news/20130510-free_skin_health_screenings_this_weekend/2459549/In the interest of Skin Cancer Awareness Month, Sam's Clubs nationwide are offering free skin health screenings on Saturday, May 11 from 11am-3pm to members and non members. Those screened are being encouraged to take results to a dermatologist to get proper treatment and advice after their exams. T
- OXY Unveils Overhauled Acne Lineshttps://practicaldermatology.com/news/20130507-oxy_unveils_overhauled_acne_lines/2459550/After 30 years, the OXY brand (Mentholatum Company) has had a makeover and now offers two distinct lines grouped by active ingredients designed to either kill acne (benzoyl peroxide) or provide maintenance for acne-prone skin (salicylic acid). The OXY Maximum Action line includes, among others, OXY
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- AcneFree Products with Micro-Benzoyl Peroxide Now Availablehttps://practicaldermatology.com/news/20130430-acnefree_products_with_micro-benzoyl_peroxide_now_available/2459553/Formulated with Advanced Micro-Benzoyl Peroxide, new AcneFree Clear Skin Products from Valeant Consumer Products are formulated to effectively target acne with less irritation. Three kits are available: The AcneFree 24 Hour Acne Clearing System (AcneFree
- Restoration's ARTAS Earns Edison Gold Medal for Innovationhttps://practicaldermatology.com/news/20130430-restorations_artas_earns_edison_gold_medal_for_innovation/2459554/Restoration Robotics, Inc.'s ARTAS® System was honored with the Gold medal at the 26th Edison Awards, the international awards ceremony honoring innovators and innovation, in the science/medical category. The Edison Awards celebrate human creati
- Lambrolizumab Designated as Breakthrough Therapyhttps://practicaldermatology.com/news/20130429-lambrolizumab_designated_as_breakthrough_therapy/2459556/Merck & Co. received breakthrough therapy designation from the US Food and Drug Administration for its lambrolizumab drug as a treatment of patients with advanced melanoma. Lambrolizumab is Merck's investigational antibody therapy targeting Programm